Advertisement

Management of Small Bowel Neuroendocrine Tumors

  • Michele A. Riordon
  • Calvin H. L. LawEmail author
Chapter

Abstract

Small bowel neuroendocrine tumors are clinically challenging to detect and are often found incidentally or with metastatic disease. Specific imaging is used to detect and localize these tumors, and biochemical tests can be used to help identify patients at risk of a carcinoid crisis. Treatment is often multimodal and is determined by tissue differentiation and Ki-67 index.

Keywords

Neuroendocrine Small bowel Midgut Carcinoid tumor Serotonin Somatostatin Ki-67 index 

References

  1. 1.
    Strosberg JR, Weber JM, Feldman M, et al. Prognostic validity of the American Joint Committee on cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol. 2013;31:420–5.CrossRefGoogle Scholar
  2. 2.
    Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumors. Lancet Oncol. 2008;9:61–72.CrossRefGoogle Scholar
  3. 3.
    Hallet J, Law CHL, Cukier M, et al. Exploring the risking incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121:589–97.CrossRefGoogle Scholar
  4. 4.
    Pape UF, Berndt U, Muller-Nordhorn J. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2008;15:183–97.CrossRefGoogle Scholar
  5. 5.
    Raphael MJ, Chan DL, Law C, et al. Principles of diagnosis and management of neuroendocrine tumors. CMAJ. 2017;189:E398–404.CrossRefGoogle Scholar
  6. 6.
    Onaitis MW, Kirshbom PM, Hayward TZ, et al. Gastrointestinal carcinoids: characteristics by site of origin and hormone production. Ann Surg. 2000;232:549–56.CrossRefGoogle Scholar
  7. 7.
    Grimaldi F, Fazio N, Attanasio R, et al. Italian Association of Clinical endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Investig. 2014;37:875–909.CrossRefGoogle Scholar
  8. 8.
    Stridsberg M, Eriksson B, Oberg K, et al. A comparison between three commercial kits for chromogranin a measurements. J Endocinol. 2003;177:337–41.CrossRefGoogle Scholar
  9. 9.
    Singh S, Law C. Chromogranin a: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2012;6:313–34.CrossRefGoogle Scholar
  10. 10.
    Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86:858–65.CrossRefGoogle Scholar
  11. 11.
    Woltering EA, Wright AE, Stevens MA, et al. Development of effective prophylaxis against intraoperative carcinoid crisis. J Clin Anesth. 2016;32:189–93.CrossRefGoogle Scholar
  12. 12.
    Condron ME, Pommier SJ, Pommier RF. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery. 2016;159:358–65.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of SurgeryRoyal Victoria Regional Health CentreBarrieCanada
  2. 2.Department of Surgical OncologySunnybrook Health Sciences CentreTorontoCanada

Personalised recommendations